PSORCON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PSORCON (PSORCON).
Psorcon (diflorasone diacetate) is a corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins. It inhibits the release of arachidonic acid, thereby decreasing the formation of prostaglandins and leukotrienes, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Topical diflorasone diacetate is absorbed percutaneously. The extent of absorption depends on factors such as application site, integrity of skin, and use of occlusive dressings. Hepatic metabolism is likely via the cytochrome P450 system, though specific enzymes are not well documented. |
| Excretion | Primarily renal (about 70% as unchanged drug and metabolites); biliary/fecal elimination of approximately 30%. |
| Half-life | Terminal elimination half-life is approximately 2 hours (range 1.5–3 hours) after topical application; clinical significance: short half-life allows twice-daily dosing. |
| Protein binding | Approximately 90–95% bound to plasma proteins, mainly albumin. |
| Volume of Distribution | Not well characterized for topical use; systemic Vd estimated around 0.5 L/kg, indicating distribution into total body water. |
| Bioavailability | Topical: Bioavailability is minimal (estimated <1%) through intact skin; increased with occlusive dressings or inflamed skin (up to 5%). |
| Onset of Action | Topical: Onset of clinical effect (e.g., reduction of inflammation) occurs within 1–2 weeks of regular application; no systemic onset data applicable. |
| Duration of Action | Duration of action: 12–24 hours after topical application, supporting twice-daily dosing; clinical note: continuous use beyond 2 weeks should be re-evaluated due to risk of adrenal suppression. |
Apply a thin layer to affected skin twice daily. For scalp conditions, use lotion or shampoo as directed.
| Dosage form | OINTMENT |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy in children have not been established; use only if potential benefit outweighs risk. |
| Geriatric use | Use with caution due to increased risk of skin atrophy; apply sparingly to small areas for short durations. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PSORCON (PSORCON).
| Breastfeeding | It is not known whether topical diflorasone diacetate is excreted in human milk. Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Because many drugs are excreted in human milk, caution should be exercised when PSORCON is administered to a nursing woman. Use on smallest area for shortest duration. No M/P ratio available. |
| Teratogenic Risk | Topical corticosteroids like PSORCON (diflorasone diacetate) are assigned Pregnancy Category C. Systemic absorption is minimal with topical application, but extensive use, large areas, or occlusive dressings may increase absorption. In animal reproduction studies, corticosteroids have shown teratogenic effects (cleft palate, skeletal abnormalities) at relatively low doses. There are no adequate and well-controlled studies in pregnant women. Therefore, PSORCON should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester: Theoretical risk based on animal data; avoid if possible. Second and third trimesters: Use with caution, limit to small areas, short duration, and avoid occlusive dressings. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to diflorasone diacetate or any component of the formulation","Untreated skin infections (bacterial, fungal, viral, or parasitic)"]
| Precautions | ["Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression","Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can occur","Pediatric patients may be more susceptible to systemic toxicity","Prolonged use may cause local atrophy, striae, telangiectasias, and purpura","Do not use in the presence of untreated bacterial, fungal, viral, or parasitic infections"] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of maternal adrenal suppression (fatigue, hypotension, hyponatremia) if large areas are treated or occlusive dressings used. Monitor for fetal growth restriction if prolonged use. Assess for skin atrophy, striae, or secondary infection. No specific fetal monitoring is required with brief, limited use. |
| Fertility Effects | No human studies on fertility effects. In animal studies, corticosteroids may impair fertility (e.g., altered estrous cycles, implantation failure) at high systemic doses. Topical use with minimal absorption is unlikely to significantly affect fertility. |